A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The study will compare the relative bioavailability (rate and extent of absorption) of 200
mg/5 mL Azithromycin oral suspension manufactured by TEVA Pharmaceutical Industries Ltd.;
distributed by TEVA Pharmaceuticals USA with that of 200 mg/5 mL ZITHROMAX®.